Topics

LPCN Awaits FDA Word, NKTR On Track, All's Well With Five Prime's FPT155

22:48 EST 10 Nov 2019 | RTTNews

Today's Daily Dose brings you news about Alnylam's new positive efficacy results from its ongoing phase II open-label extension (OLE) study of Lumasiran for the treatment of primary hyperoxaluria type; Five Prime's initial safety data from its phase I clinical trial of FPT155 in patients with advanced solid tumors and Lipocine's much-awaited catalyst.

Original Article: LPCN Awaits FDA Word, NKTR On Track, All's Well With Five Prime's FPT155

NEXT ARTICLE

More From BioPortfolio on "LPCN Awaits FDA Word, NKTR On Track, All's Well With Five Prime's FPT155"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...